Skip to main content

Advertisement

Log in

Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods

  • Special Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

New studies and literature continue to emerge on the management of mucositis secondary to cancer therapy. The evidence-based clinical practice guidelines for mucositis were first published in 2004 and updated in 2007 and 2014 by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The existing 2014 guidelines for mucositis are being updated in line with new literature to inform clinical practice. This paper describes the materials and methods employed for the comprehensive updates to the guidelines for managing mucositis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046

    Article  PubMed  Google Scholar 

  2. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025

    Article  PubMed  Google Scholar 

  3. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831

    Article  CAS  PubMed  Google Scholar 

  4. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bowen JM, Elad S, Hutchins RD, Lalla RV (2013) Methodology for the MASCC/ISOO mucositis clinical practice guidelines update. Support Care Cancer 21:303–308

    Article  CAS  PubMed  Google Scholar 

  6. Elad S, Bowen J, Zadik Y, Lalla RV (2013) Development of the MASCC/ISOO clinical practice guidelines for mucositis: considerations underlying the process. Support Care Cancer 21:309–312

    Article  PubMed  Google Scholar 

  7. Grossetta Nardini HK, Wang L (2018) The Yale MeSH analyzer. In: Editor (ed)^(eds) Book The Yale MeSH Analyzer. Yale University, City

  8. Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754

    Article  CAS  PubMed  Google Scholar 

  9. Hadorn DC, Baker D (1994) Development of the AHCPR-sponsored heart failure guideline: methodologic and procedural issues. Jt Comm J Qual Improv 20:539–547

    CAS  PubMed  Google Scholar 

  10. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC et al (1995) Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail 1:183–187

    Article  CAS  PubMed  Google Scholar 

  11. Somerfield M, Padberg J, Pfister D, Bennett C, Recht A, Smith T, Weeks J, Winn R, Durant J (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comments 4:881–886

    Google Scholar 

  12. Aapro M, Ashbury F, Lalla R, Peterson D, Molassiotis A, Rapoport B, Young A (2016) The MASCC guidelines policy. In: Editor (ed)^(eds) Book The MASCC guidelines policy. Multinational Association of Supportive Care in Cancer, City

  13. Buntzel J, Schuth J, Kuttner K, Glatzel M (1998) Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6:155–160

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Vinisha Ranna.

Ethics declarations

Conflict of interest

Employees of commercial entities were not eligible to serve on this MASCC Guidelines Panel. All authors completed a conflict of interest disclosure form and conflicts are disclosed in the guideline’s publications. The authors disclose no conflict of interest (VR, KC, LP, DC). PB has served an advisory role for Galera Therapeutics. SE reports no conflict in regard to mucositis, and consulting to Falk Pharma as the Medical Expert for a clinical trial about oral chronic graft versus host disease. RVL has served as a consultant for Colgate Oral Pharmaceuticals, Galera Therapeutics, Ingalfarma SA, Monopar Therapeutics, Mundipharma, and Sucampo Pharma; has received research support to his institution from Galera Therapeutics, Novartis, Oragenics, and Sucampo Pharma; and has received stock in Logic Biosciences.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ranna, V., Cheng, K.K.F., Castillo, D.A. et al. Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. Support Care Cancer 27, 3933–3948 (2019). https://doi.org/10.1007/s00520-019-04891-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-019-04891-1

Keywords

Navigation